Abstract | BACKGROUND: METHODS: In this open-label, randomised, phase 3 trial, eligible patients were ⩾18 years, chemonaïve, East Asian, light ex-smokers/never-smokers with advanced non-squamous non-small cell lung cancer, an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 and unknown epidermal growth factor receptor (EGFR) mutation status who enrolled at 12 sites in Asia. Patients randomly received (1:1) pemetrexed (500 mg/m(2)) plus cisplatin (75mg/m(2)) for six 21-day cycles, followed by gefitinib maintenance or gefitinib monotherapy (250 mg/day). Patient tissue was retrospectively analysed for EGFR mutations. This study is registered with ClinicalTrials.gov, NCT01017874. FINDINGS: Between 23rd November 2009 and 27th April 2012, 253 patients entered, and 236 patients were randomly assigned to and treated with PC therapy (N=114) and gefitinib monotherapy (N=118). Between-arm baseline characteristics were balanced. PFS was not significantly different between treatment arms (p=0.217). The unadjusted hazard ratio (HR) was 0.85 (95% confidence interval (CI) 0.63-1.13). The HR should be cautiously interpreted as it was not constant. EGFR mutation status was determined for 74 tissue samples; 50 (67.6%) had mutations. In a pre-specified subgroup analysis, only the treatment-by-EGFR mutation interaction was significant (p=0.008) for PFS. For the entire treatment period, a higher proportion of patients in the PC/ gefitinib arm versus gefitinib experienced possibly drug-related grade 3-4 treatment-emergent adverse events (39 of 114 [34%] versus 19 of 118 [16%]; p=0.002). INTERPRETATION: In the intention-to-treat (ITT) population, PFS was not significantly different. In the biomarker-assessable population, front-line EGFR tyrosine kinase inhibitor monotherapy was not efficacious in patients with wild-type EGFR. Identification of EGFR mutation status is key in the management of advanced non-squamous non-small cell lung cancer. FUNDING: Eli Lilly and Company.
|
Authors | James Chih-Hsin Yang, Jin Hyoung Kang, Tony Mok, Myung-Ju Ahn, Vichien Srimuninnimit, Chia-Chi Lin, Dong-Wan Kim, Chun-Ming Tsai, Helen Barraclough, Sedat Altug, Mauro Orlando, Keunchil Park |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 50
Issue 13
Pg. 2219-30
(Sep 2014)
ISSN: 1879-0852 [Electronic] England |
PMID | 24953333
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 Elsevier Ltd. All rights reserved. |
Chemical References |
- Glutamates
- Protein Kinase Inhibitors
- Quinazolines
- Pemetrexed
- Guanine
- Cisplatin
- Gefitinib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Asian People
(genetics)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Cisplatin
(administration & dosage)
- Disease-Free Survival
- Female
- Gefitinib
- Glutamates
(administration & dosage)
- Guanine
(administration & dosage, analogs & derivatives)
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Pemetrexed
- Protein Kinase Inhibitors
(administration & dosage, therapeutic use)
- Quinazolines
(administration & dosage, therapeutic use)
- Young Adult
|